Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EBT (2016 - 2025)

Immucell (ICCC) has disclosed EBT for 16 consecutive years, with -$135293.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 80.68% year-over-year to -$135293.0, compared with a TTM value of $2.3 million through Sep 2025, up 161.43%, and an annual FY2024 reading of -$2.1 million, up 62.8% over the prior year.
  • EBT was -$135293.0 for Q3 2025 at Immucell, down from $503785.0 in the prior quarter.
  • Across five years, EBT topped out at $1.4 million in Q1 2025 and bottomed at -$2.3 million in Q1 2023.
  • Average EBT over 5 years is -$455496.0, with a median of -$441303.0 recorded in 2021.
  • The sharpest move saw EBT tumbled 2314.25% in 2022, then surged 431.91% in 2025.
  • Year by year, EBT stood at $75256.0 in 2021, then crashed by 2314.25% to -$1.7 million in 2022, then soared by 31.68% to -$1.1 million in 2023, then soared by 145.73% to $520591.0 in 2024, then tumbled by 125.99% to -$135293.0 in 2025.
  • Business Quant data shows EBT for ICCC at -$135293.0 in Q3 2025, $503785.0 in Q2 2025, and $1.4 million in Q1 2025.